Eleftheria A. Anastasopoulou
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
Journal: Anticancer research
Published: January 28, 2023
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
Journal: Future oncology (London, England)
Published: August 05, 2022
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Journal: Breast cancer research and treatment
Published: October 27, 2019
Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Journal: Journal for immunotherapy of cancer
Published: May 15, 2017
Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model.
Journal: Cancer immunology, immunotherapy : CII
Published: March 23, 2017
Further insight into AE37 peptide vaccination in prostate cancer.
Journal: Future science OA
Published: January 13, 2017
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Journal: Journal for immunotherapy of cancer
Published: December 15, 2016
Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
Journal: Anticancer research
Published: October 20, 2016
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2016
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
Journal: Oncoimmunology
Published: March 04, 2016
Life as an early career researcher: interview with Eleftheria Anastasopoulou.
Journal: Future science OA
Published: February 09, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 20, 2015
Last Updated: 09/26/2026